Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasisPatrik Andersson, Yihai Cao|JCI Insight|2018Cited by 118
Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta CellLaurent Knerr, Shalini Andersson, Maria Ölwegård-Halvarsson et al.|Journal of the American Chemical Society|2021Cited by 72
Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety AssessmentYann Tessier, Laurence O. Whiteley, William E. Achanzar et al.|Nucleic Acid Therapeutics|2020Cited by 14
Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry SurveyJoel D. Parry, Yi Yan Yang, Tod A. Harper et al.|Nucleic Acid Therapeutics|2025Cited by 2
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based TherapeuticsJennifer D. Sisler, Tod A. Harper, Patrik Andersson et al.|International Journal of Toxicology|2026Cited by 1